Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

NCT07751133 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1500

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
mHSPC
mCRPC

Interventions

DRUG: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy

Sponsor

University College, London

Collaborators

[object Object]
[object Object]
[object Object]